Sirukumab  (Synonyms: CNTO-136)

Sirukumab (CNTO-136) is a humanized monoclonal anti-IL6 (Interleukin Related) IgG1κ antibody. Sirukumab binds to IL6, preventing IL6-mediated signal transduction and activation of transcriptional activators, thereby blocking the downstream biological effects of IL6. Sirukumab can be used in the study of active lupus nephritis and rheumatoid arthritis^[1][2].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

IL-6/IFNb2

Sirukumab binds specifically to human IL-6 with high affinity of 0.175 pM, and exhibits no effect with other ligands that transmit signals through gp130^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Sirukumab (0.5-5 mg/kg) reduces serum amyloid A level in IL-6 induced mouse inflammation model^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

3569  [NCBI]

P05231

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

144.58 kDa

1194585-53-9

Liquid

Colorless to light yellow

[Sirukumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Immobilized Human IL-6 Protein can bind Sirukumab. The EC₅₀ for this effect is 1.86 ng/mL.
• 
  Flow cytometric analysis of 1.5×10⁶ Siha cells labeling Sirukumab (HY-P99316, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Brad H Rovin, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Treatment With Sirukumab (CNTO 136) in Patients With Active Lupus Nephritis. Arthritis Rheumatol. 2016 Sep;68(9):2174-83.  [Content Brief]

  [2]. Bartoli F, et al. Sirukumab for the treatment of rheumatoid arthritis: update on sirukumab, 2018[J]. Expert Review of Clinical Immunology, 2018, 14(7): 539-547.  [Content Brief]

  [3]. Gardner D, et al. THU0042 Preclinical Characterization of Sirukumab, a Human Monoclonal Antibody that Targets Human Interleukin-6 Signaling[J]. Annals of the Rheumatic Diseases, 2015, 74: 207.